1.
|
Leenhardt L, Grosclaude P and
Chérié-Challine L: Thyroid Cancer Committee: Increased incidence of
thyroid carcinoma in France: a true epidemic or thyroid nodule
management effects? Report from the French Thyroid Cancer
Committee. Thyroid. 14:1056–1060. 2004. View Article : Google Scholar
|
2.
|
Sprague BL, Warren Andersen S and
Trentham-Dietz A: Thyroid cancer incidence and socioeconomic
indicators of health care access. Cancer Causes Control.
19:585–593. 2008. View Article : Google Scholar : PubMed/NCBI
|
3.
|
Xing M: BRAF mutation in thyroid cancer.
Endocr Relat Cancer. 12:245–262. 2005. View Article : Google Scholar : PubMed/NCBI
|
4.
|
Liu Z, Hou P, Ji M, et al: Highly
prevalent genetic alterations in receptor tyrosine kinases and
phosphatidylinositol 3-kinase/akt and mitogen-activated protein
kinase pathways in anaplastic and follicular thyroid cancers. J
Clin Endocrinol Metab. 93:3106–3116. 2008. View Article : Google Scholar
|
5.
|
Van Raamsdonk CD, Griewank KG, Crosby MB,
et al: Mutations in GNA11 in uveal melanoma. N Engl J Med.
363:2191–2199. 2010.PubMed/NCBI
|
6.
|
Palavalli LH, Prickett TD, Wunderlich JR,
et al: Analysis of the matrix metalloproteinase family reveals that
MMP8 is often mutated in melanoma. Nat Genet. 41:518–520. 2009.
View Article : Google Scholar : PubMed/NCBI
|
7.
|
Wei X, Walia V, Lin JC, et al: Exome
sequencing identifies GRIN2A as frequently mutated in melanoma. Nat
Genet. 43:442–446. 2011. View
Article : Google Scholar : PubMed/NCBI
|
8.
|
Prickett TD, Wei X, Cardenas-Navia I, et
al: Exon capture analysis of G protein-coupled receptors identifies
activating mutations in GRM3 in melanoma. Nat Genet. 43:1119–1126.
2011. View
Article : Google Scholar : PubMed/NCBI
|
9.
|
Hou P, Liu D and Xing M: Genome-wide
alterations in gene methylation by the BRAF V600E mutation in
papillary thyroid cancer cells. Endocr Relat Cancer. 18:687–697.
2011. View Article : Google Scholar : PubMed/NCBI
|
10.
|
Brinckerhoff CE and Matrisian LM: Matrix
metalloproteinases: a tail of a frog that became a prince. Nat Rev
Mol Cell Biol. 3:207–214. 2002. View
Article : Google Scholar : PubMed/NCBI
|
11.
|
Egeblad M and Werb Z: New functions for
the matrix metalloproteinases in cancer progression. Nat Rev
Cancer. 2:161–174. 2002. View
Article : Google Scholar : PubMed/NCBI
|
12.
|
Freije JM, Balbín M, Pendás AM, Sánchez
LM, Puente XS and López-Otín C: Matrix metalloproteinases and tumor
progression. Adv Exp Med Biol. 532:91–107. 2003. View Article : Google Scholar : PubMed/NCBI
|
13.
|
Orrico A, Galli L, Faivre L, et al:
Aarskog-Scott syndrome: clinical update and report of nine novel
mutations of the FGD1 gene. Am J Med Genet A. 152A:313–318. 2010.
View Article : Google Scholar : PubMed/NCBI
|
14.
|
Whitehead IP, Abe K, Gorski JL and Der CJ:
CDC42 and FGD1 cause distinct signaling and transforming
activities. Mol Cell Biol. 18:4689–4697. 1998.PubMed/NCBI
|
15.
|
Murugan AK, Dong J, Xie J and Xing M: MEK1
mutations, but not ERK2 mutations, occur in melanomas and colon
carcinomas, but none in thyroid carcinomas. Cell Cycle.
8:2122–2124. 2009. View Article : Google Scholar : PubMed/NCBI
|
16.
|
Murugan AK and Xing M: Anaplastic thyroid
cancers harbor novel oncogenic mutations of the ALK gene. Cancer
Res. 71:4403–4411. 2011. View Article : Google Scholar : PubMed/NCBI
|
17.
|
Neff RL, Farrar WB, Kloos RT and Burman
KD: Anaplastic thyroid cancer. Endocrinol Metab Clin North Am.
37:525–538. 2008. View Article : Google Scholar
|
18.
|
Murugan AK, Dong J, Xie J and Xing M:
Uncommon GNAQ, MMP8, AKT3, EGFR, and PIK3R1 mutations in thyroid
cancers. Endocr Pathol. 22:97–102. 2011. View Article : Google Scholar : PubMed/NCBI
|
19.
|
Mitsiades CS, Kotoula V, Poulaki V, et al:
Epidermal growth factor receptor as a therapeutic target in human
thyroid carcinoma: mutational and functional analysis. J Clin
Endocrinol Metab. 91:3662–3666. 2006. View Article : Google Scholar
|